These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 32303592)

  • 21. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
    Le Bert N; Tan AT; Kunasegaran K; Tham CYL; Hafezi M; Chia A; Chng MHY; Lin M; Tan N; Linster M; Chia WN; Chen MI; Wang LF; Ooi EE; Kalimuddin S; Tambyah PA; Low JG; Tan YJ; Bertoletti A
    Nature; 2020 Aug; 584(7821):457-462. PubMed ID: 32668444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
    Xu W; Wang M; Yu D; Zhang X
    Front Immunol; 2020; 11():565278. PubMed ID: 33013929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.
    Sanami S; Zandi M; Pourhossein B; Mobini GR; Safaei M; Abed A; Arvejeh PM; Chermahini FA; Alizadeh M
    Int J Biol Macromol; 2020 Dec; 164():871-883. PubMed ID: 32682041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suboptimal SARS-CoV-2-specific CD8
    Habel JR; Nguyen THO; van de Sandt CE; Juno JA; Chaurasia P; Wragg K; Koutsakos M; Hensen L; Jia X; Chua B; Zhang W; Tan HX; Flanagan KL; Doolan DL; Torresi J; Chen W; Wakim LM; Cheng AC; Doherty PC; Petersen J; Rossjohn J; Wheatley AK; Kent SJ; Rowntree LC; Kedzierska K
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24384-24391. PubMed ID: 32913053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2.
    Rakib A; Sami SA; Islam MA; Ahmed S; Faiz FB; Khanam BH; Marma KKS; Rahman M; Uddin MMN; Nainu F; Emran TB; Simal-Gandara J
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33147821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
    Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
    Front Immunol; 2020; 11():1663. PubMed ID: 32754160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
    Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).
    Olwenyi OA; Dyavar SR; Acharya A; Podany AT; Fletcher CV; Ng CL; Reid SP; Byrareddy SN
    J Mol Med (Berl); 2020 Oct; 98(10):1369-1383. PubMed ID: 32808094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Grifoni A; Weiskopf D; Ramirez SI; Mateus J; Dan JM; Moderbacher CR; Rawlings SA; Sutherland A; Premkumar L; Jadi RS; Marrama D; de Silva AM; Frazier A; Carlin AF; Greenbaum JA; Peters B; Krammer F; Smith DM; Crotty S; Sette A
    Cell; 2020 Jun; 181(7):1489-1501.e15. PubMed ID: 32473127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
    Sarkar B; Ullah MA; Johora FT; Taniya MA; Araf Y
    Immunobiology; 2020 May; 225(3):151955. PubMed ID: 32517882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
    To KK; Tsang OT; Leung WS; Tam AR; Wu TC; Lung DC; Yip CC; Cai JP; Chan JM; Chik TS; Lau DP; Choi CY; Chen LL; Chan WM; Chan KH; Ip JD; Ng AC; Poon RW; Luo CT; Cheng VC; Chan JF; Hung IF; Chen Z; Chen H; Yuen KY
    Lancet Infect Dis; 2020 May; 20(5):565-574. PubMed ID: 32213337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.
    Ovsyannikova IG; Haralambieva IH; Crooke SN; Poland GA; Kennedy RB
    Immunol Rev; 2020 Jul; 296(1):205-219. PubMed ID: 32658335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis.
    Tomita Y; Ikeda T; Sato R; Sakagami T
    Immun Inflamm Dis; 2020 Dec; 8(4):684-694. PubMed ID: 33047883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A role for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in transplant patients.
    Poulton K; Wright P; Hughes P; Savic S; Welberry Smith M; Guiver M; Morton M; van Dellen D; Tholouli E; Wynn R; Clark B
    Int J Immunogenet; 2020 Aug; 47(4):324-328. PubMed ID: 32623831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions.
    Liu G; Carter B; Bricken T; Jain S; Viard M; Carrington M; Gifford DK
    Cell Syst; 2020 Aug; 11(2):131-144.e6. PubMed ID: 32721383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.